Particle size and activation threshold: a new dimension of danger signaling.
about
Current understanding of interactions between nanoparticles and the immune systemMessenger RNA-based vaccines: progress, challenges, applicationsCytokines as biomarkers of nanoparticle immunotoxicityData Mining as a Guide for the Construction of Cross-Linked Nanoparticles with Low Immunotoxicity via Control of Polymer Chemistry and Supramolecular Assembly.Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA.Endosomal escape and siRNA delivery with cationic shell crosslinked knedel-like nanoparticles with tunable buffering capacities.Developing mRNA-vaccine technologies.Serotype-specific Binding Properties and Nanoparticle Characteristics Contribute to the Immunogenicity of rAAV1 VectorsMultifunctional hierarchically assembled nanostructures as complex stage-wise dual-delivery systems for coincidental yet differential trafficking of siRNA and paclitaxelMonocytes and macrophages in tissue repair: Implications for immunoregenerative biomaterial designInteractions of nanomaterials with the immune system.Information processing during phagocytosis.Particle platforms for cancer immunotherapy.Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.mRNA transcript therapy.Dendritic cell-based vaccine research against cancer.Concise Review: Application of In Vitro Transcribed Messenger RNA for Cellular Engineering and Reprogramming: Progress and Challenges.Function of extracellular vesicle-associated miRNAs in metastasis.Viral and Synthetic RNA Vector Technologies and Applications.Internalization routes of cell-penetrating melanoma antigen peptides into human dendritic cells.Introduction to RNA Vaccines.Exploiting 4-sulphate N-acetyl galactosamine decorated gelatin nanoparticles for effective targeting to professional phagocytes in vitro and in vivo.Graphene and the Immune System: A Romance of Many Dimensions.A new role for microRNAs, as ligands of Toll-like receptors.Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets.Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques.Time to cast a larger net.mRNA vaccines - a new era in vaccinology.PLGA-encapsulated perfluorocarbon nanoparticles for simultaneous visualization of distinct cell populations by 19F MRI.Analysis of Nanoparticle-Adjuvant Properties In Vivo.Generation of Immunostimulating 130 nm Protamine-RNA nanoparticles.Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches.Pentoxifylline, dexamethasone and azithromycin demonstrate distinct age-dependent and synergistic inhibition of TLR- and inflammasome-mediated cytokine production in human newborn and adult blood in vitro.Exosome-delivered microRNAs promote IFN-α secretion by human plasmacytoid DCs via TLR7.
P2860
Q26345204-228312F0-E919-4C7A-B252-267578085F1CQ27012738-25234670-A646-4AE1-88DD-318DE4345786Q28383550-69797843-FAE5-44BD-93CB-23C5213D1DEBQ30958719-841C8245-BB07-4111-BF29-23F2E428CAC3Q35620919-3542F54A-07B4-4CCD-83BB-6BDA3D9AE4F0Q36638988-E9F8D449-46A9-4950-B018-BC15F5B2606DQ36684597-3CD5F474-C9D4-46C0-8FA1-7F9048EE0024Q36756695-3E768566-6C00-4568-81B9-13E7F59BB5A9Q36925898-1CDE714F-6F69-4B64-8483-16B184AF1A11Q36981636-AD5A40C1-28B8-4444-A086-A6F77A9E206DQ37965056-E4665554-FF89-4D0B-9C82-C161C7379AE3Q38018843-8E0493CA-EE86-4227-94E7-DF85EAF8788BQ38114060-AFB5906C-218C-42DC-A603-3B14F0ED28ECQ38199151-ECECFF1B-FE2D-411A-A934-D3BA26E07FE6Q38264088-BEB8BD12-F17A-4B8F-A0B1-3933801C1A08Q38281782-144645CC-56E0-42BD-B24D-D51AC246D533Q38850538-1D9CE8AF-3BFC-43E6-B8D8-DFCF609A8B43Q38862245-9B2EED6C-BC79-4018-A0BB-D3215AD8CBB6Q38885624-DE40780F-C2F7-4E98-B239-1889A3BD3505Q39039132-17FBF91A-129A-42AD-B22A-54A753EA23F1Q39041939-7A99796A-EC12-4DC3-9419-AAFCE3FEC68DQ39269782-5C4067CB-B02A-437E-9074-5C7EF346D2A7Q39403516-DD6E51C8-05BE-4DCD-802F-BFC6DE1BAF25Q41295458-20C39920-FA47-41F2-9C54-52E20B614BB7Q41835523-E17EAA51-3C5A-4240-87D3-DE3BD2CF8523Q41993335-E7C334FB-944F-44CF-ACC6-F8CBDCAC684BQ46095609-14E796F2-FAFF-4123-B8EB-99B2FB408669Q47736893-FB49A34F-B095-4EBA-A714-380977FDFD63Q48657577-A1A2795C-2674-4E96-B50D-5F86AF3C059DQ50078038-D254C278-D3B1-4C28-B607-A9933A00A644Q51253926-C68D3E93-C723-49D7-AF21-68E9EEC2F178Q53755427-4B078275-ECA7-4108-B06B-6AF0094CA764Q54223958-969E99BD-991F-4648-B63E-3038CA4E577BQ55322197-E5F03F63-7DC7-40D7-99FA-E26E945D0664
P2860
Particle size and activation threshold: a new dimension of danger signaling.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Particle size and activation threshold: a new dimension of danger signaling.
@en
Particle size and activation threshold: a new dimension of danger signaling.
@nl
type
label
Particle size and activation threshold: a new dimension of danger signaling.
@en
Particle size and activation threshold: a new dimension of danger signaling.
@nl
prefLabel
Particle size and activation threshold: a new dimension of danger signaling.
@en
Particle size and activation threshold: a new dimension of danger signaling.
@nl
P2093
P1433
P1476
Particle size and activation threshold: a new dimension of danger signaling.
@en
P2093
Alessandra Curioni
Alexander Knuth
Anne Greet Bittermann
Lorna Rettig
Lotta von Boehmer
Steve Pascolo
P304
P356
10.1182/BLOOD-2009-11-247817
P407
P577
2010-03-19T00:00:00Z